Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Interest & Investment Income (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Interest & Investment Income for 5 consecutive years, with $1.7 million as the latest value for Q1 2026.

  • For Q1 2026, Interest & Investment Income fell 34.24% year-over-year to $1.7 million; the TTM value through Mar 2026 reached $6.1 million, down 54.47%, while the annual FY2025 figure was $7.0 million, 53.53% down from the prior year.
  • Interest & Investment Income hit $1.7 million in Q1 2026 for Phathom Pharmaceuticals, up from $1.2 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $4.3 million in Q1 2024 and bottomed at $7000.0 in Q1 2022.
  • Average Interest & Investment Income over 5 years is $2.0 million, with a median of $1.7 million recorded in 2026.
  • Year-over-year, Interest & Investment Income surged 20757.14% in 2023 and then plummeted 65.7% in 2025.
  • Phathom Pharmaceuticals' Interest & Investment Income stood at $1.3 million in 2022, then skyrocketed by 160.14% to $3.3 million in 2023, then increased by 4.84% to $3.5 million in 2024, then tumbled by 65.7% to $1.2 million in 2025, then surged by 44.19% to $1.7 million in 2026.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $1.7 million, $1.2 million, and $1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.